Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Acne
Interventions: adapalene/benzoyl peroxide, Topical Gel Vehicle; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 9 Years to 11 Years
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 20
States / cities: Birmingham, Alabama • San Diego, California • Santa Rosa, California + 17 more

Conditions: Peripheral Vascular Diseases, Arterial Occlusive Diseases, Ischemia, Graft Occlusion, Vascular, Hyperplasia
Interventions: CGT003 (E2F Duplex Decoy); Drug
Lead sponsor: Anesiva, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 116
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more

Conditions: Non-alcoholic Fatty Liver Disease, Liver Cirrhosis
Interventions: CC-90001, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 64
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 48 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Peer Mentoring; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 30 Years to 75 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Mild Cognitive Impairment, Accidental Falls, Aging
Interventions: dual-task tai ji quan, standard tai ji quan, stretching; Behavioral
Lead sponsor: Oregon Research Institute; Other
Eligibility: 65 Years to 95 Years
Enrollment: 336 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Springfield, Oregon

Conditions: Sepsis, Electronic Health Records, Clinical Decision Support Systems
Interventions: Nurse SIRS alert, Prescribing clinician SIRS alert; Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 12,284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Parkinson's Disease
Interventions: nicotine, placebo comparator; Drug · Other
Lead sponsor: Neuraltus Pharmaceuticals, Inc.; Industry
Eligibility: 30 Years to 83 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angelis, California • Oxnard, California + 9 more

Conditions: Cystitis, Interstitial, Painful Bladder Syndrome
Interventions: LiRIS®, LiRIS Placebo; Combination Product
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 31
States / cities: Mobile, Alabama • Escondido, California • Los Angeles, California + 27 more

Conditions: Depressive Disorder, Major
Interventions: Radafaxine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 21
States / cities: Peoria, Arizona • Scottsdale, Arizona • Garden Grove, California + 18 more

Conditions: Premature Birth of Newborn, Enterocolitis, Necrotizing
Interventions: Ampicillin, Gentamicins, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: Up to 6 Hours
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Iron Deficiency, Fibromyalgia
Interventions: Injectafer, Placebo; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Franklin, Tennessee

Conditions: Smallpox, Anthrax
Interventions: BioCASES and BioTESTS; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 9
States / cities: Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 6 more

Conditions: Pancreatitis, Diabetes
Interventions: Sitagliptin, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy Volunteer
Interventions: Brensocatib, Moxifloxacin, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Lupus Nephritis
Interventions: Mycophenolate Mofetil; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 8 Years to 20 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 19
States / cities: San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 14 more

Conditions: Obesity
Interventions: Survodutide, Placebo; Combination Product
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 14
States / cities: Birmingham, Alabama • Northridge, California • Orange, California + 11 more

Conditions: Ischemic Heart Disease
Interventions: GS-6615, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Dystonic Cerebral Palsy
Interventions: ITB Titration Protocol, Ventral Dorsal Rhizotomy, Deep Brain Stimulation, Research Assessments and Study Monitoring; Drug · Procedure · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 21 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: COVID-19
Interventions: Degarelix, Saline; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 85 Years · Male only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 14
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 11 more

Conditions: Hand Surgery, Wrist Surgery, Elbow Surgery, Fracture Fixation, Dupuytren Contracture, Finger Fracture, Wrist Arthropathy, Distal Radius Fracture
Interventions: Liposomal bupivacaine (LB), Dexamethasone; Drug
Lead sponsor: St. Luke's Hospital, Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Bethlehem, Pennsylvania

Conditions: Episodic Migraine
Interventions: Eptinezumab, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 15
States / cities: Stamford, Connecticut • Gulf Breeze, Florida • Hialeah, Florida + 12 more

Conditions: Prevention & Control
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Aspirin placebo, Rivaroxaban placebo, Pantoprazole, Pantoprazole placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 27,395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 53
States / cities: Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 49 more

Conditions: Cervical Intraepithelial Neoplasia
Interventions: Imiquimod, Loop Electrosurgical Excision Procedure; Drug · Procedure
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 21 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: San Diego, California

Conditions: Tumors
Interventions: Hands-free, user-controlled robotic system intended to assist in the planning and advancement of an instrument during CT guided percutaneous procedures. T; Device
Lead sponsor: Xact Robotics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Burlington, Massachusetts

Search by objective public record fields.

Epiduo Pediatric Acne Study

Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures

Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

Using Peer Mentors to Support PACT Team Efforts to Improve Diabetes Control

A Study of Dual-task Exercise Training to Prevent Falls Among Older Adults With Mild Cognitive Impairment

Sepsis Electronic Prompting for Timely Intervention and Care for Inpatients

Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy

A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome

An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder

A Randomized Controlled Trial Investigating if Antibiotic Use in the First 48 Hours of Life Adversely Impacts the Preterm Infant Microbiome

Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia

VHA Clinicians and Bioterror Events: Interactive Web-based Learning

Sitagliptin Therapy to Improve Outcomes After Islet Autotransplant

A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight

A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects

Intrathecal Baclofen and Pediatric Dystonia

Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization

The Efficacy of Liposomal Bupivacaine in Ultrasound Guided Supraclavicular Nerve Blocks for Hand and Wrist Surgery

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix

XACT ACE Observational Registry